EU and US could reach trade deal this weekend - Reuters
LUXEMBOURG - Moolec Science SA (NASDAQ:MLEC), a developer of animal proteins and nutritional oils through molecular farming, disclosed on Monday that it has signed a Business Combination Agreement with agricultural firm Bioceres Group Limited and other entities. According to InvestingPro data, Bioceres currently operates with a market capitalization of $259.62 million and maintains impressive gross profit margins of 41.55%. The all-stock transaction will result in Moolec becoming the parent company of an enlarged corporate structure.
The agreement, signed on April 17, 2025, will see shareholders of Bioceres Group, Nutrecon LLC, and Gentle Technologies Corp transfer their holdings to Moolec. In return, Moolec will issue up to 87 million new shares and 5 million warrants to the shareholders of the contributed entities.
Federico Trucco, CEO of Bioceres Crop Solutions Corp, remarked on the potential of molecular farming to address agricultural challenges and enhance sustainability. Juan Sartori, Founder and Chairman of Union Group, supported the vision of creating a new kind of company for the 21st century, combining science, scale, and sustainability.
Post-merger, Moolec will be uniquely positioned in the agricultural value chain, with a focus on seed and microbe modification to impact land and water resource utilization positively. The combined entities will manage a portfolio of over 800 patents and 550 product registrations, representing more than half a billion dollars in annual sales to over 50 countries. InvestingPro analysis shows Bioceres currently generates annual revenue of $407.73 million, though analysts anticipate some sales decline in the current year. For deeper insights into the company’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
Moolec’s CFO, José López Lecube, highlighted the transaction’s potential for growth, cost efficiencies, revenue increase, and product diversification. Additionally, the merger is expected to enlarge Moolec’s investor base.
Moolec will continue developing its molecular farming products and expand into biological agricultural solutions, advanced R&D services, and emerging technologies for grain and biomass transformation.
The transaction, approved by the boards of all participating entities, is anticipated to close in the second quarter of 2025, subject to regulatory approvals and Moolec’s shareholder approval. The deal’s consummation will involve an equity exchange, with Bioceres Group’s shareholders receiving up to 80,590,280 shares of Moolec, and shareholders of Nutrecon and Gentle Tech receiving a combined 6,475,000 shares and 5,000,000 warrants.
This news is based on a press release statement from Moolec Science SA. With Bioceres currently trading at $4.14 and showing signs of being undervalued according to InvestingPro Fair Value metrics, investors seeking detailed analysis can explore over 12 additional ProTips and comprehensive financial metrics available through the InvestingPro platform.
In other recent news, Bioceres Crop Solutions Corp reported financial results for the second quarter of fiscal year 2024, revealing a significant shortfall in earnings and revenue compared to forecasts. The company reported an earnings per share (EPS) of $0.0095, falling short of the anticipated $0.18, while revenue reached $106.7 million, missing the expected $155.92 million. This represents a 24% decline in revenue year-over-year, attributed to a contraction in the Argentine agricultural market. Meanwhile, Moolec Science SA announced a strategic business combination involving Bioceres Group PLC, Nutrecon LLC, and Gentle Technologies Corp, aiming to enhance market reach and capabilities. The merger includes detailed financial disclosures, with relief from certain reporting requirements granted by the SEC. Additionally, Bioceres received approval from the U.S. Environmental Protection Agency for its Rinotec insecticide platform, marking a regulatory milestone that complements its commercialization efforts in Brazil. Analyst firm Canaccord Genuity adjusted Bioceres’ stock price target to $6.50 from $7.00, maintaining a Buy rating, reflecting strategic developments within the company. These updates underscore ongoing changes and challenges faced by Bioceres and its associated entities in the agricultural sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.